Afraxis Hopes Experimental Fragile X Drug Could Apply To Other CNS Diseases
This article was originally published in The Pink Sheet Daily
Biotech believes that inactivation of p21-activated kinase may address underlying cause of Fragile X syndrome.
You may also be interested in...
Afraxis Inc. is developing p21-activated kinase (PAK) inhibitors, initially for Fragile X syndrome, a genetic condition involving changes in the X chromosome that can lead to cognitive impairment and autism-like behaviors. The start-up thinks treatment of this orphan indication may be a gateway to developing PAK inhibitors for closely related conditions, such as autism and other central nervous system disorders like Alzheimer's disease and schizophrenia.
Eli Lilly said August 17 it would halt development of its Phase III Alzheimer's drug candidate semagacestat, casting some doubt on the efficacy of novel gamma secretase inhibitor drugs and slowing Lilly's late-stage pipeline as the company struggles to replace future revenues that will be lost to drugs going off patent
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.